Open AccessMucormycosis In COVID-19: Does It Even Exist
Author(s) -
Muhammad Wajad Munir,
Abdur Rehman,
Sheharyar Raashid,
Quratulain Tanveer,
Hassan Mumtaz
Publication year - 2022
Publication title -
pakistan biomedical journal
Language(s) - English
Resource type - Journals
eISSN - 2709-2798
pISSN - 2709-278X
DOI - 10.54393/pbmj.v5i1.296
Subject(s) - medicine , vomiting , diarrhea , surgery , pneumonia , abdominal pain , eschar , diabetic ketoacidosis , cellulitis , dermatology , diabetes mellitus , pediatrics , endocrinology
The WHO named the COVID-19 epidemic, which was caused by the SARS-CoV-2 coronavirus, a global pandemic on March 11, 2020. Doctors noted an increase in incidences of Mucormycosis towards the beginning of May 2020. Case Presentation: A 48-year-old female patient complained of fever, body aches, vomiting, abdominal pain, diarrhea and no weakness or numbness. A chest x-ray revealed bilateral pneumonia. Treatment with steroids, antibiotics, remdesivir and anticoagulation was initiated. Patient was diagnosed with sinusitis with right orbital cellulitis, moderated proptosis and frank osseous erosions. Concomitantly patient developed a scrapable black eschar on the upper palate. Patient further underwent FESS surgery of the maxillary sinuses of both sides. Patient was sent home after an appreciable recovery and put on a close follow up list. Conclusion: Diabetes mellitus sufferers are particularly susceptible to this fungus's deadly effects. For individuals with mucromycosis, swift and precise diagnostic facilities, medical aid and a speedy yet coordinated response are all recommended.